Biofermin (4517 JP) - Taisho (4581 JP): Merger Is a Done Deal
Taisho Pharma and subsidiary Biofermin (4517) have agreed to merge. The vote looks like a done deal. This is a short-dated rate of return trade.
503 Views
Taisho Pharma Seems the Best Suitor for Takeda’s Japan OTC Business
It was reported by several news media outlets that Blackstone, Bain Capital, CVC Capital Partners and Taisho Pharmaceutical are among the final...
631 Views
Taisho To Launch Another DHG Pharma Tender
After the close on 28 February 2019, Taisho Pharmaceutical Holdings (4581 JP)announced it would launch another Tender Offer, this time to purchase...
833 Views
Taisho Frontrunner to Acquire BMS’s French OTC Business
Event – Bristol Myers Squibb Co (BMY US)'s  French OTC business UPSA has been on the block since June 2018. According to a December 17, 2018...
863 Views
Japan: Fortnightly Update - And So It Goes
AND SO IT GOES - After our eight-day 4.5% 'Thanksgiving rally', the market reverted to recent type and promptly fell 6.5% to Tuesday's low, which...
629 Views